זיפאדהרה 210 מ"ג

Nazione: Israele

Lingua: ebraico

Fonte: Ministry of Health

Principio attivo:

OLANZAPINE 210 MG

Commercializzato da:

ELI LILLY ISRAEL LTD

Codice ATC:

N05AH03

Forma farmaceutica:

POWDER FOR SUSPENSION FOR INJECTION

Via di somministrazione:

I.M

Prodotto da:

LILLY PHARMA FERT. & DISTRIB. GmbH & Co. KG

Gruppo terapeutico:

OLANZAPINE

Indicazioni terapeutiche:

Zypadhera is indicated for the treatment of schizophrenia.The use of Zypadhera is limited to patients who have been diagnosed as non-compliant regarding taking prescribed medicines and as a consequence are prone to outbursts of psychotic episodes .Zypadhera is NOT to be used in patients whose condition is adequately controlled with oral Zyprexa .Zypadhera is available only through a restricted program which will be conducted according to Zypadhera EU Risk Management Plan.For a patient to receive treatment, the prescribers , injection administrators, pharmacists and patients must all be trained on the appropriate elements of the Zypadhera Risk Management Plan. The Zypadhera Risk Management plan has been developed to enable the safe use of Zypadhera in patients, including the management of those patients who develop Post-Injection Delirium and Sedation Syndrome. In addition to mandating label language around this risk, this plan includes education and training activities to the following target audience as appr

Data dell'autorizzazione:

2010-12-01